-
COST-EFFECTIVENESS ANALYSIS OF TRIFLURIDINE/TIPIRACIL AS THIRD-LINE TREATMENT FOR HEAVILY PRETREATED METASTATIC GASTRIC CANCER IN JAPAN...
Aug 11, 2026, 15:45 PM -
A GENAI-BASED VISUALIZATION PLATFORM FOR SYSTEMATIC LITERATURE REVIEW INSIGHTS
Aug 11, 2026, 15:45 PM -
COST-UTILITY ANALYSIS OF LEFT ATRIAL APPENDAGE OCCLUSION VERSUS ANTICOAGULANT THERAPY FOR ATRIAL FIBRILLATION PATIENTS AT HIGH RISK OF STROKE AND MAJOR BLEEDING IN THAILAND...
Aug 11, 2026, 15:45 PM -
(PRESTO) PHYSICIAN REASONS FOR SUBCUTANEOUS ANTI-HER2 OPT-IN: FACTORS ASSOCIATED WITH PHYSICIANS’ PREFERENCE IN USING SUBCUTANEOUS FORMULATION OF ANTI-HER2 TREATMENT IN PERSONS WITH BREAST CANCER
Aug 11, 2026, 15:45 PM -
PRE-EXTRACTION INTERRUPTION OF BONE-TARGETING AGENTS AND OSTEONECROSIS OF THE JAW IN CANCER PATIENTS WITH BONE METASTASES: A TARGET TRIAL EMULATION WITH DATA-DRIVEN HETEROGENEITY ANALYSIS
Aug 11, 2026, 15:45 PM -
PATIENT PREFERENCES FOR AMYLOID-TARGETING THERAPIES OF ALZHEIMER’S DISEASE IN CHINA...
Aug 11, 2026, 15:45 PM -
SCENARIO-SPECIFIC VALUES OF STATISTICAL LIFE IN JAPAN: EVIDENCE FROM WILLINGNESS-TO-PAY ELICITATION FOR HEALTH, DISASTER, AND SAFETY RISKS
Aug 11, 2026, 15:45 PM -
APPROACH TO PRICE INNOVATIVE DRUGS...
Aug 11, 2026, 15:45 PM -
PATIENT INVOLVEMENT IN RARE DISEASE HEALTH TECHNOLOGY ASSESSMENT (HTA): REAL-WORLD PRACTICES IN AUSTRALIA, SINGAPORE, AND TAIWAN
Aug 11, 2026, 15:45 PM -
THE HIDDEN COST OF NON-ADHERENCE: CLINICAL AND ECONOMIC BURDEN OF SEVELAMER DISCONTINUATION IN DIALYSIS PATIENTS IN THE MEXICAN PUBLIC HEALTH SYSTEM
Aug 11, 2026, 15:45 PM -
CONSTRUCTION OF A VALUE ASSESSMENT FRAMEWORK FOR NEW ANTIDIABETIC DRUGS TO SUPPORT EVIDENCE-INFORMED DECISION-MAKING
Aug 11, 2026, 15:45 PM -
REDUCTION OF PSYCHIATRIC HOSPITALIZATION AFTER REVISIONS FOR MENTAL HEALTH AND WELFARE ACT
Aug 11, 2026, 15:45 PM -
AFFORDABILITY OF BIOLOGIC ADD-ON THERAPY FOR SEVERE EOSINOPHILIC ASTHMA IN THAILAND: A BUDGET IMPACT ANALYSIS OF MEPOLIZUMAB AND BENRALIZUMAB...
Aug 11, 2026, 15:45 PM -
UNIFORM PAYMENT FOR SELECTED DRGS ACROSS HOSPITAL LEVELS: EVIDENCE FROM CHINA’S DRG-BASED PAYMENT REFORM
Aug 11, 2026, 15:45 PM -
NMPA NATIONAL REGISTRATION GAPS AND FDA-TO-NMPA APPROVAL LAG AMONG FDA-APPROVED RARE DISEASE THERAPIES: AN INDICATION-LEVEL ANALYSIS OF CHINA’S 207-CONDITION RARE DISEASE CATALOG, 2001-2024
Aug 11, 2026, 15:45 PM -
THE VALUE OF TARGETED ORAL PEPTIDES IN IMMUNOLOGY: A TARGETED LITERATURE REVIEW AND QUALITATIVE SYNTHESIS
Aug 11, 2026, 15:45 PM -
COST‑EFFECTIVENESS OF 20- AND 15‑VALENT PNEUMOCOCCAL CONJUGATE VACCINES FOR CHILDREN: A SYSTEMATIC REVIEW AND META-ANALYSIS OF ECONOMIC EVALUATIONS
Aug 11, 2026, 15:45 PM -
OPIOIDS AND PSYCHOTROPIC MEDICATIONS CO-PRESCRIBING FOR CHRONIC NON-CANCER PAIN PATIENTS IN TAIWAN BEFORE AND AFTER MEDICATION GUIDELINE CHANGES: AN INTERRUPTED TIME SERIES ANALYSIS
Aug 11, 2026, 15:45 PM -
SEVERITY INDEX FOR CHILDREN WITH DEVELOPMENTAL EPILEPTIC ENCEPHALOPATHY AND QUALITY OF LIFE OF CARERS...
Aug 11, 2026, 15:45 PM -
INCORPORATING PATIENT PREFERENCES INTO THE VALUE ASSESSMENT OF NOVEL LUNG CANCER DRUGS: EVIDENCE FROM A DISCRETE CHOICE EXPERIMENT
Aug 11, 2026, 15:45 PM
